In the complex world of pharmaceutical manufacturing, the quality and availability of key intermediates are paramount to the successful development and production of life-saving medications. For drugs like Vemurafenib, a targeted therapy for specific cancers, the journey from raw materials to the final API is a carefully orchestrated process that relies heavily on precise chemical synthesis.

At the heart of Vemurafenib synthesis lies a crucial building block: N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide, identified by its CAS number 918504-27-5. This compound, with its intricate heterocyclic structure and specific functional groups, is indispensable for constructing the active pharmaceutical ingredient (API) that targets BRAF mutations.

As a leading chemical intermediate manufacturer and supplier based in China, we understand the critical importance of purity, consistency, and reliable supply for our pharmaceutical clients. Our production of N-(3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide is held to the highest standards, ensuring a minimum assay of ≥98.0%. This level of purity is not merely a specification; it is a prerequisite for efficient downstream processing and the ultimate efficacy of the final drug product.

For procurement managers and research scientists, sourcing such critical intermediates involves more than just finding a supplier. It means partnering with a manufacturer that demonstrates a deep understanding of pharmaceutical quality requirements, regulatory landscapes, and supply chain resilience. When you choose to buy our CAS 918504-27-5 intermediate, you are opting for a product backed by rigorous quality control and a commitment to timely delivery.

The molecule's structure, C17H14BrF2N3O3S, with a molecular weight of 458.27700, makes it a complex but essential component. Its availability in a white to yellow crystalline powder form simplifies handling and integration into various synthesis protocols. We offer this product in standard 25 kg drums, but are also equipped to meet customized packaging requirements to suit diverse production scales, from R&D batches to commercial manufacturing.

The development of targeted therapies like Vemurafenib represents a significant advancement in cancer treatment. Therefore, ensuring a stable and high-quality supply of its precursors, such as our sulfonamide derivative, is a responsibility we take very seriously. We continuously strive to be a dependable manufacturer and supplier for the global pharmaceutical industry, facilitating your research and production goals with our expertise and resources. If you are looking to purchase this vital intermediate, we invite you to reach out for a quote and sample, and experience the difference of partnering with a committed supplier.